GMH, a bit off-topic, and I'll try and improve on this discussion and my thoughts in the future, but one point that I keep coming back to is patent expirations and ways of extending those dates. Other companies may full well see value from acquiring Iovance so as to combine it with their products in order to gain patent protection for additional years (Merck, Keytruda).
This is an excerpt from an old article, but it's still relevant on a number of fronts: "Combinations Does one and one make three? That is the question drug companies are asking themselves these days as they face huge threats to their earnings from patent expirations. One novel solution: combining two or more successful drugs into one tablet and marketing it as a whole new product. Schering-Plough is looking to extend its giant franchise in its allergy drug Claritin by combining it with Singulair, an asthma drug from Merck. Schering-Plough is not alone. Eli Lilly, Pfizer, and Warner-Lambert are all looking to create new combinations of drugs to bolster earnings and sustain growth. Companies are getting a lot more creative in ways to sustain the product lifespan of drugs. The medical community looks at it as a kind of cookbook medicine. They have an aversion to combination drugs. Nonetheless, it is a strategy that has proved successful for some drug makers..."
News 
Market Data 
Discover 
